1. Homepage
  2. Equities
  3. France
  4. Euronext Paris
  5. Nicox SA.
  6. Summary
    COX   FR0013018124

NICOX SA.

(COX)
  Report
Real-time Euronext Paris  -  11:35 2022-07-01 am EDT
1.720 EUR   +0.12%
06/22Nicox Extraordinary General Meeting of July 11, 2022
GL
06/22Nicox Extraordinary General Meeting of July 11, 2022
AQ
06/15NICOX : Suggested agenda and summary of the resolutions submitted to the approval of the Extraordinary shareholder meeting (translation for information purposes)
PU
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Real-time Quote. Real-time Euronext Paris
06/27/2022 06/28/2022 06/29/2022 06/30/2022 07/01/2022 Date
1.81(c) 1.85(c) 1.79(c) 1.718(c) 1.72(c) Last
24 087 34 764 29 043 40 633 93 607 Volume
0.00% +2.21% -3.24% -4.02% +0.12% Change
More quotes
Estimated financial data (e)
Sales 2022 9,03 M 9,39 M 9,39 M
Net income 2022 -20,3 M -21,2 M -21,2 M
Net cash position 2022 2,49 M 2,59 M 2,59 M
P/E ratio 2022 -3,66x
Yield 2022 -
Sales 2023 12,8 M 13,3 M 13,3 M
Net income 2023 -12,4 M -12,9 M -12,9 M
Net Debt 2023 8,21 M 8,54 M 8,54 M
P/E ratio 2023 -6,14x
Yield 2023 -
Capitalization 74,3 M 77,3 M 77,3 M
EV / Sales 2022 7,96x
EV / Sales 2023 6,45x
Nbr of Employees 33
Free-Float 89,1%
More Financials
Company
Nicox S.A. is an ophthalmology company developing innovative solutions to help maintain vision and improve ocular health. Nicox S.A.'s lead program in clinical development is NCX 470, a novel, second-generation nitric oxide-donating prostaglandin analog, for lowering intraocular pressure in patients with glaucoma or ocular hypertension. The company is also developing NCX 4251, a proprietary formulation of... 
Sector
Pharmaceuticals
Calendar
07/11 | 08:00amShareholder meeting
More about the company
Ratings of Nicox SA.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
-
More Ratings
All news about NICOX SA.
06/22Nicox Extraordinary General Meeting of July 11, 2022
GL
06/22Nicox Extraordinary General Meeting of July 11, 2022
AQ
06/15NICOX : Suggested agenda and summary of the resolutions submitted to the approval of the E..
PU
06/15NICOX : How to participate in the Extraordinary shareholder meeting
PU
06/14NICOX : 2022 Ordinary Shareholder Meeting
GL
06/14NICOX : 2022 Ordinary Shareholder Meeting
GL
06/03NICOX : 2022 Extraordinary Shareholder Meeting
GL
06/03NICOX : 2022 Extraordinary Shareholder Meeting
AQ
06/03Ophthalmology Group Nicox To Release Data From Late-stage Glaucoma Drug Trial In Novemb..
MT
06/03Nicox Accelerates Topline Results from NCX 470 Mont Blanc Phase 3 Glaucoma Trial to Nov..
GL
06/03Nicox Accelerates Topline Results from NCX 470 Mont Blanc Phase 3 Glaucoma Trial to Nov..
AQ
06/03Nicox S.A. Accelerates Topline Results from NCX 470 Mont Blanc Phase 3 Glaucoma Trial t..
CI
05/31NICOX SA. : Monthly statement on outstanding equity shares and voting rights
CO
05/16Ophthalmology Group Nicox Appoints New CEO, Chairman
MT
05/16Nicox Announces a New Governance Structure
GL
More news
News in other languages on NICOX SA.
06/28NICOX : AGO 28 juin – Procès-verbal de l'Assemblée générale ordinaire sur deuxième c..
06/28NICOX : AGO 28 juin – Quorum de l'Assemblée générale ordinaire sur deuxième convocat..
06/28NICOX : Scrutin de l'Assemblée générale ordinaire sur deuxième convocation le 28 juin 2022
06/28NICOX : Feuille de présence de l'Assemblée générale ordinaire sur deuxième convocation le ..
06/23NICOX : Avis de convocation publié au BALO le 22 juin 2022
More news
Chart NICOX SA.
Duration : Period :
Nicox SA. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NICOX SA.
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 2
Last Close Price 1,72 €
Average target price 11,50 €
Spread / Average Target 569%
EPS Revisions
Managers and Directors
Andreas Rutger Segerros Chief Executive Officer
Sandrine Gestin Vice President-Finance
Michele Garufi Chairman
José Boyer Head-Research & Development
Doug Hubatsch Chief Scientific Officer
Sector and Competitors
1st jan.Capi. (M$)
NICOX SA.-32.68%77
MERCK KGAA-27.00%74 935
KYOWA KIRIN CO. LTD.-3.19%12 062
SK BIOPHARMACEUTICALS CO., LTD.-27.57%4 240
BETTA PHARMACEUTICALS CO., LTD.-30.24%3 452
YUHAN CORPORATION-9.82%2 930